| Type 2 Diabetes Mellitus |
1 |
1 |
| GLP-1 Receptor Agonist |
0 |
0.77 |
| Obesity |
0 |
0.55 |
| Cardiometabolic Risk Factors |
0 |
0.5 |
| Receptors |
0 |
0.45 |
| Weight Management |
0 |
0.37 |
| NHS |
0 |
0.36 |
| SGLT2 Inhibitor |
0 |
0.36 |
| Biliary Disease |
0 |
0.28 |
| Liver |
0 |
0.27 |
| Weight Loss |
0 |
0.27 |
| Aminotransferase |
0 |
0.26 |
| Fatty Liver |
0 |
0.26 |
| Liver Disease |
0 |
0.26 |
| Continuous Glucose Monitoring |
0 |
0.25 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.24 |
| Metabolic Syndrome |
0 |
0.19 |
| Patient Safety |
0 |
0.19 |
| Adverse Effects |
0 |
0.18 |
| Hospital |
0 |
0.18 |
| UK Site Content |
0 |
0.18 |
| Contraception |
0 |
0.13 |
| Hemoglobin A1c |
0 |
0.13 |
| Pregnancy |
0 |
0.13 |
| Renal Disease |
0 |
0.13 |
| Hypertension |
0 |
0.11 |
| Hemodialysis |
0 |
0.1 |
| Amputation |
0 |
0.09 |
| Blood |
0 |
0.09 |
| Body Mass Index |
0 |
0.09 |
| Cardiovascular disease |
0 |
0.09 |
| Dialysis |
0 |
0.09 |
| Disease Management |
0 |
0.09 |
| Dyslipidemia |
0 |
0.09 |
| Epidemic |
0 |
0.09 |
| Fertility |
0 |
0.09 |
| Hemoglobin |
0 |
0.09 |
| Kidney |
0 |
0.09 |
| Referral |
0 |
0.09 |
| Type 1 Diabetes Mellitus |
0 |
0.09 |
| Young Adult |
0 |
0.09 |
| Cardiovascular Risk Management |
0 |
0.06 |
| Lipids Management |
0 |
0.06 |